First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma treated
Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “We are very excited to have dosed the first participant in this highest dose level cohort of our theranostic neuroblastoma trial in the US, having successfully completed cohort 3 very recently. We hope that the increase in administered activity between cohorts 3 and cohort 4 will have a significant impact on radiation-sensitive disease, such as neuroblastoma, and we look forward to generating the data from the 375MBq/kg body weight dose.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.